Thea Pharma has launched Iyuzeh in the U.S. for the treatment of primary open-angle glaucoma or ocular hypertension.
“Iyuzeh brings similar efficacy of traditional latanoprost, formulated without preservatives, to help eye care providers confidently address their treatment goals of lowering intraocular pressure for people with POAG and OHT,” Susan Benton, president of Thea Pharma, said in a press release.
In randomized controlled clinical trials, Iyuzeh (latanoprost ophthalmic solution 0.005%) lowered IOP in patients with primary open-angle glaucoma or ocular hypertension with a